Qualigen Therapeutics (QLGN) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): N/A
• Revenue Growth: N/A
• EPS Growth: 84.34%
• Country: US
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: N/A
• EPS (TTM): -55.30
• Shares Outstanding: N/A
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.57
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.24
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 31 Underperform
• Price Target: ―

Qualigen Therapeutics' overall stock score is low due to significant financial challenges, including declining revenue, substantial losses, and financial instability. The bearish technical analysis further dampens the outlook. However, recent corporate events like strategic investments and leadership changes provide a slight positive outlook on future potential improvements.

Positive Factors

Strategic Investment

Investing in NanoSynex's technology could enhance Qualigen's diagnostic capabilities, opening new revenue streams in a growing market.

Leadership Strength

The addition of Graydon Bensler to the board brings financial expertise, potentially improving capital management and strategic decision-making.

Market Expansion Potential

Qualigen's investment in NanoSynex positions it to benefit from market expansion in the EU and US, enhancing long-term growth prospects.

Negative Factors

Financial Instability

Negative equity indicates financial instability, limiting Qualigen's ability to invest in growth opportunities without external financing.

Operational Cash Burn

Ongoing cash burn threatens sustainability, requiring improved cash management and operational efficiency to stabilize finances.

Revenue Decline

Persistent revenue decline challenges Qualigen's ability to fund operations and invest in R&D, impacting long-term growth potential.

Qualigen Therapeutics Business Overview & Revenue Model

Company Description

How the Company Makes Money

Qualigen Therapeutics generates revenue through multiple streams, primarily focusing on the development and commercialization of its therapeutic products. The company earns money by advancing its drug candidates through clinical trials and securing partnerships or licensing agreements with larger pharmaceutical companies. These collaborations often involve upfront payments, milestone payments based on the achievement of clinical and regulatory goals, and royalties on product sales. Additionally, Qualigen may derive revenue from its diagnostic technologies, which are used in clinical settings and research institutions. The company's financial performance is significantly influenced by its ability to successfully bring its drug candidates to market and establish strategic partnerships within the pharmaceutical industry.

Qualigen Therapeutics Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	5.20M	4.98M	5.65M	4.31M
Gross Profit	0.00	0.00	-4.50K	680.80K	1.32M	-2.88M
EBITDA	-6.48M	-5.24M	-11.30M	-13.84M	-22.34M	-11.16M
Net Income	-7.23M	-6.16M	-13.42M	-21.03M	-17.90M	-20.42M
Balance Sheet
Total Assets	43.47M	4.69M	2.03M	19.08M	22.84M	29.13M
Cash, Cash Equivalents and Short-Term Investments	38.78M	1.17M	401.80K	3.17M	17.54M	23.98M
Total Debt	3.24M	0.00	1.30M	1.76M	1.68M	630.30K
Total Liabilities	4.92M	2.01M	4.14M	10.32M	6.27M	10.83M
Stockholders Equity	38.55M	2.68M	-2.10M	7.24M	16.56M	18.29M
Cash Flow
Free Cash Flow	-7.10M	-6.33M	-10.30M	-13.57M	-14.87M	-9.97M
Operating Cash Flow	-7.10M	-6.33M	-10.30M	-13.25M	-14.73M	-9.76M
Investing Cash Flow	-2.82M	-1.91M	4.22M	-183.76K	-141.36K	-160.56K
Financing Cash Flow	48.30M	9.01M	-550.00K	2.91M	8.43M	33.76M

Qualigen Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.88
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QLGN, the sentiment is Negative. The current price of 2.88 is above the 20-day moving average (MA) of 2.72, below the 50-day MA of 3.62, and below the 200-day MA of 3.22, indicating a bearish trend. The MACD of -0.21 indicates Negative momentum. The RSI at 39.96 is Neutral, neither overbought nor oversold. The STOCH value of 17.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QLGN.

Qualigen Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VYNE	45 Neutral	$8.34M	-0.36	-70.67%	―	6.29%	7.42%
XBIO	43 Neutral	$6.49M	-1.43	-57.43%	―	13.30%	22.70%
INAB	34 Underperform	$7.49M	-0.16	-189.72%	―	―	70.57%
QLGN	31 Underperform	―	―	-39.69%	―	―	84.34%

Qualigen Therapeutics Corporate Events

Qualigen Therapeutics Invests in NanoSynex’s Growth

On January 28, 2025, Qualigen Therapeutics announced its participation as the first investor in the 2025 bridge funding round for NanoSynex, which aims to raise up to $500,000. This investment supports the development of NanoSynex’s Antimicrobial Susceptibility Testing technology, which is expected to significantly enhance diagnostic speed and accuracy, potentially expanding the market to $4.7 billion by 2027. NanoSynex plans to enter the EU and US markets by 2027 and 2028, respectively, with a promising pipeline and four patents protecting its technology.

Qualigen Therapeutics Appoints Graydon Bensler to Board

Graydon Bensler has been appointed as an independent board member, bringing over seven years of financial consulting and management experience. A Chartered Financial Analyst, Bensler co-founded an Ed Tech company and held key roles in investor relations and investment banking. His expertise in capital markets and public company compliance is expected to benefit the board significantly.